ArticleJournal of enzyme inhibition and medicinal chemistry2022
Biological investigation of
Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 52 citations in OpenAlex.
- Influence of substitution patterns on the antimicrobial properties of pyrrole sulfonamide scaffolds.Frontiers in chemistry · 2026Article
- Establishment, validation and application of a spectrophotometric method for the accurate determination of carbonic anhydrase activity.RSC advances · 2025Article
- Dual inhibition of carbonic anhydrases VA and VII by silychristin and isosilybin A from Silybum marianum: A potential antiobesity strategy.Archiv der Pharmazie · 2025Article
- Preliminary Investigations on Acyl Hydrazones Bearing Sulfonamides as Inhibitors of the Human Carbonic Anhydrase Isoforms I, II, IX, and XII.Anti-cancer agents in medicinal chemistry · 2025Article
- Antimicrobial proteins from oyster hemolymph improve the efficacy of conventional antibiotics.PloS one · 2025Article
- Lasamide Containing Sulfonylpiperazines as Effective Agents for the Management of Glaucoma Associated Symptoms.ChemMedChem · 2024Article
- Potent Antimicrobial Azoles: Synthesis, In Vitro and In Silico Study.Antibiotics (Basel, Switzerland) · 2024Article
- Phenolic compounds from pumpkin pulp: Extraction optimization and biological properties.Food chemistry: X · 2024Article
- Lasamide, a Potent Human Carbonic Anhydrase Inhibitor from the Market: Inhibition Profiling and Crystallographic Studies.ACS medicinal chemistry letters · 2024Article
- Azobenzenesulfonamide Carbonic Anhydrase Inhibitors as New Weapons to FightPharmaceuticals (Basel, Switzerland) · 2024Article
- Benzenesulfonamide decorated dihydropyrimidin(thi)ones: carbonic anhydrase profiling and antiproliferative activity.RSC medicinal chemistry · 2024Article
- Novel 2,4-Dichloro-5-sulfamoylbenzoic Acid Oxime Esters: First Studies as Potential Human Carbonic Anhydrase Inhibitors.ACS medicinal chemistry letters · 2024Article
- Synthesis, crystal structure and Hirshfeld analysis ofActa crystallographica. Section E, Crystallographic communications · 2024Article
- Article
- Investigation of novel alkyl/benzyl (4-sulphamoylphenyl)carbamimidothioates as carbonic anhydrase inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Photoactivatable Heptamethine-Based Carbonic Anhydrase Inhibitors Leading to New Anti-Antibacterial Agents.International journal of molecular sciences · 2023Article
- Small Structural Differences Govern the Carbonic Anhydrase II Inhibition Activity of Cytotoxic Triterpene Acetazolamide Conjugates.Molecules (Basel, Switzerland) · 2023Article
- Benzenesulfonamides Incorporating Hydantoin Moieties Effectively Inhibit Eukaryoticand Human Carbonic Anhydrases.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The enormous burden of the COVID-19 pandemic in economic and healthcare terms has cast a shadow on the serious threat of antimicrobial resistance, increasing the inappropriate use of antibiotics and shifting the focus of drug discovery programmes from antibacterial and antifungal fields. Thus, there is a pressing need for new antimicrobials involving innovative modes of action (MoAs) to avoid cross-resistance rise. Thiosemicarbazones (TSCs) stand out due to their easy preparation and polypharmacological application, also in infectious diseases. Recently, we reported a small library of TSCs (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.